2,4-difluoro-5-nitroacetophenone | 179011-35-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,4-difluoro-5-nitroacetophenone
• 英文别名: 1-(2,4-Difluoro-5-nitrophenyl)ethan-1-one；1-(2,4-difluoro-5-nitrophenyl)ethanone
• CAS: 179011-35-9
• 化学式: C₈H₅F₂NO₃
• 分子量: 201.129
• InChiKey: JFMFYUJRUXKEIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  62.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,4-difluoro-5-nitroacetophenone 在 ammonium hydroxide 作用下， 以 乙醇 为溶剂， 生成 4-amino-2-fluoro-5-nitroacetophenone
  参考文献：
  名称：

  Ohmori; Sakamoto; Kubota, Journal of Medicinal Chemistry, 1994, vol. 37, # 4, p. 467 - 475

  摘要：

  DOI：
• 作为产物：
  描述：

  2',4'-二氟苯乙酮 在 硝酸 作用下， 生成 2,4-difluoro-5-nitroacetophenone
  参考文献：
  名称：

  Ohmori; Sakamoto; Kubota, Journal of Medicinal Chemistry, 1994, vol. 37, # 4, p. 467 - 475

  摘要：

  DOI：

文献信息

• Tricyclic Compounds As mPGES-1 Inhibitors
  申请人：Gharat Laxmikant A.

  公开号：US20120108583A1

  公开（公告）日：2012-05-03

  The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

  本发明涉及式(I)的三环化合物或其药用可接受的盐作为mPGES-1抑制剂。这些化合物是微粒体前列腺素E合成酶-1（mPGES-1）酶的抑制剂，因此在治疗各种疾病或病况引起的疼痛和/或炎症方面具有用处，如哮喘、骨关节炎、类风湿性关节炎、急性或慢性疼痛和神经退行性疾病。
• 1,2,3,4-tetrahydroquinoxalinedione derivative
  申请人：Yamanouchi Pharmaceuticals Co., Ltd.

  公开号：US06096743A1

  公开（公告）日：2000-08-01

  A 1,2,3,4-tetrahydroquinoxalinedione derivative represented by the following formula (I) or salt thereof, an NMDA-glycine receptor and/or AMPA receptor antagonist or kainic acid neurotoxicity inhibitor containing the derivative or salt. In addition, a pharmaceutical composition comprising said compound and a pharmaceutically acceptable carrier: ##STR1## wherein the substituents are as described in the specification.

  由以下公式（I）表示的1,2,3,4-四氢喹诺酮二酮衍生物或其盐，含有该衍生物或盐的NMDA-甘氨酸受体和/或AMPA受体拮抗剂或卡因酸神经毒性抑制剂。此外，包括所述化合物和药学上可接受的载体的药物组合物：##STR1##其中取代基如说明书中所述。
• NEW COMPOUNDS
  申请人：PRIEPKE Henning

  公开号：US20120214786A1

  公开（公告）日：2012-08-23

  This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin E 2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, M, W, R 1 , R 2 , R 6 , R 7 , R 8 have meanings given in the description.

  本发明涉及公式I化合物，它们作为微粒体前列腺素E2合酶-1（mPGES-1）的抑制剂的用途，包含它们的药物组合物，以及它们作为治疗和/或预防炎症性疾病和相关症状的药物的用途。A、M、W、R1、R2、R6、R7、R8在描述中有所解释。
• 1,2,3,4-TETRAHYDROQUINOXALINEDIONE DERIVATIVE
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0784054A1

  公开（公告）日：1997-07-16

  A 1,2,3,4-tetrahydroquinoxalinedione derivative represented by the following formula (I) or salt thereof, an NMDA-glycine receptor and/or AMPA receptor antagonist or kainic acid neurotoxicity inhibitor containing the derivative or salt. In addition, a pharmaceutical composition comprising said compound and a pharmaceutically acceptable carrier. wherein symbols in the above formula represent the following meanings, respectively: X: N, CH, R: an imidazolyl group or a di-lower alkylamino group, R1: (1) a halogen atom, a nitro group, a cyano group, a carboxyl group, an amino group, a mono- or di-lower alkylamino group, a lower alkanoyl group, a lower alkylthio group, a lower alkylsulfinyl group, a lower alkylsulfonyl group or a carbamoyl group, (2) a lower alkyl group or lower alkoxyl group which may be substituted by a halogen atom, a carboxyl group or an aryl group, (3) a phenyloxy group which may be substituted by a lower alkoxycarbonyl group or a carboxyl group, R2: a hydroxyl group, a lower alkoxyl group, an amino group or a mono- or di-lower alkylamino group, A: a lower alkylene group which may be substituted or a group represented by the formula -O-B-, and B: a lower alkylene group,    with the proviso that the case wherein R represents an imidazolyl group, R1 represents a cyano group, A represents an ethylene group and R2 represents a hydroxyl group is excluded.

  一种由下式（I）代表的 1，2，3，4-四氢喹喔啉二酮衍生物或其盐，一种含有该衍生物或盐的 NMDA-甘氨酸受体和/或 AMPA 受体拮抗剂或凯尼酸神经毒性抑制剂。此外，还包括上述化合物和药学上可接受的载体的药物组合物。 其中，上式中的符号分别代表以下含义： X：N，CH、 R：咪唑基团或二低级烷基氨基、 R1: (1) 卤素原子、硝基、氰基、羧基、氨基、单或双低级烷基氨基、低级烷酰基、低级烷硫基、低级烷基亚磺酰基、低级烷基磺酰基或氨基甲酰基、 (2) 可被卤素原子、羧基或芳基取代的低级烷基或低级烷氧基、 (3) 可被低级烷氧基羰基或羧基取代的苯氧基、 R2：羟基、低级烷氧基、氨基或单或双低级烷基氨基、 A：可被取代的低级亚烷基或由式-O-B-代表的基团，以及 B：低级亚烷基、 但 R 代表咪唑基、R1 代表氰基、A 代表乙烯基和 R2 代表羟基的情况除外。
• US6096743A
  申请人：——

  公开号：US6096743A

  公开（公告）日：2000-08-01